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The research performed at the Department of Urology Osaka University Graduate School of Medicine
is overviewed. Renal ischemia-reperfusion (I/R) injury is inevitable in transplantation and is related to long-
term graft function. MF-1, a bifunctional hepatocyte growth factor-macrophage stimulating protein
chimera, was found to prevent apoptosis. In our study, MF-1 directly guarded cultured proximal tubular
epithelial cells from hypoxia-induced necrosis and apoptosis in vitro, and MF-1 treatment ameliorated renal
dysfunction by preventing apoptosis in rat I/R injury model. The erythropoietin molecule modified by
carbamylation (CEPO) has been identified and was demonstrated to protect several organs without increasing
the hemoglobin concentration. The therapeutic effect of CEPO was evaluated using an endothelial tube
formation assay, and a rat ischemia-reperfusion injury model. CEPO treatment induced more capillary-
like formation than EPO. CEPO-treated kidneys showed minimal tubular apoptosis with increased
peritubular capillary endothelial cells. We identified a new therapeutic approach using CEPO to protect the
kidney from ischemia-reperfusion injury by promoting angiogenesis.
(Hinyokika Kiyo 56 : 481-484, 2010)

















(hepatocyte growth factor : HGF) および Macrophage
stimulating protein (MSP) と HGF のキメラ蛋白
(Metron Factor-1 : MF-1) による移植腎保護，エリスロ
ポエチン (erythropoietin : EPO) およびカルバミル化


































































モデルを用いて体外で (ex vivo) EP 法にて腎に遺伝子
導入した．その結果，大動物においても実際に移植腎
で HGF が発現して腎線維化抑制作用を示すこと，移
植腎以外の他臓器では HGF の plasmid が PCR 法で検
出されないことを確認し，有効性と安全性を確認し
た8)．
HGF と類似した作用をもつ MSP と HGF の 2つを
元にして合成された HGF-MSP キメラ蛋白 : Metron





Fig. 1. Etiology of chronic allograft dysfunction.
Table 1. Summary of HGF research for kidney transplantation at Department of
Urology Osaka University Graduate School of Medicine
Species Experimental model Methods of administration Refference
Rat Tacrolimus induced nephrotoxicity Recombinant HGF 3
Rat Fisher→Lewis kidney transplantation Recombinant HGF 4
Rat 5/6 nephrectomy in vivo EP (skeletal muscle) 5
Rat Cyclosporine induced nephrotoxicity in vivo EP (kidney) 7
Pig Auto transplantation ex vivo EP (kidney) 8
Rat Ischemia reperfusion injury MF-1 11
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